APR 09, 2018 5:47 PM PDT

Molecularly Attacking Transthyretin Amyloidosis (ATTR)

WRITTEN BY: Nouran Amin

Transthyretin amyloidosis (ATTR) is a slowly progressive disease characterized by the buildup of abnormal deposits of a protein known as amyloid present in the body's organs and tissues. Amyloid deposits most frequently occur in the peripheral nervous system, which affect the nerves that connect the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound.

There are three distinct forms of the ATTR family which are progressive and deadly. These forms are wild-type ATTR cardiomyopathy, mutant ATTR cardiomyopathy, and ATTR polyneuropathy. All these forms are progressive and deadly, and currently no disease-modifying therapies exist that have been approved by the FDA. The progression of all types of ATTR lead to morbidity which causes loss of productivity and quality of life.

 

Now, a clinical stage biopharmaceutical company known as Eidos Therapeutics, Inc is developing novel oral therapy to treat ATTR, this oral therapy is a drug called AG10. “Our clinical data demonstrate that AG10 has a safe, well-tolerated profile and is able to stabilize 100% of plasma TTR at peak concentrations and provide average levels of stabilization greater than 95% at steady-state,” says Neil Kumar, the CEO of Eidos. “Given that increasing levels of stabilization have yielded progressively better clinical results in past trials, our near-complete levels of stabilization suggest that AG10 could be a best-in-class solution. We are targeting ATTR at its source by stabilizing TTR, an approach that is validated by genetics and clinical data.”AG10 works to target ATTR at its roots by binding and stabilizing the TTR tetramers since it is the destabilization that progresses the development of ATTR. In particular, the Eidos’ approach copies a naturally-occurring genetic mutation known as T119M that prevents high-risk individuals from developing ATTR. This form of protection works by stabilizing the TTR tetramer.

When AG10 binds to tetrameric TTR, it creates molecular bonds at the same regions as T119M, which “super-stabilizes” TTR and enhancing survival. The binding highlights the ability of AG10’s, at the highest blood concentrations, to stabilize tetrameric TTR and stop its dissociation into disease-leading TTR monomers. Previous clinical trials in ATTR demonstrate that inhibiting the generation of TTR monomers from circulating in the bloodstream significantly improves clinical outcomes. Eidos believes that AG10 may the best therapeutic treatment. “ATTR diseases are a large and growing unmet need, and together, they represent one of the largest genetically-defined diseases with inadequate standard of care,” says Rajeev Shah, the managing director and portfolio manager at RA Capital which finances Eidos. “We look forward to working with Eidos’ proven management team to bring a disease-modifying treatment for ATTR to market as quickly as possible.”

Sources: Genetics Home Reference, Drug Discovery News

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 11, 2020
Drug Discovery & Development
Engineering Drug-Producing Bacteria
AUG 11, 2020
Engineering Drug-Producing Bacteria
Researchers at Rice University worked to program a bacterium, Escherichia coli, to produce a synthetic "noncanonica ...
SEP 08, 2020
Drug Discovery & Development
New Drug Boosts Bone Growth in Children with Dwarfism
SEP 08, 2020
New Drug Boosts Bone Growth in Children with Dwarfism
A Phase III global clinical trial by the Murdoch Children’s Research Institute (MCRI) has found that a new drug, k ...
SEP 16, 2020
Drug Discovery & Development
Generic Cholesterol-Lowering Drugs Save Money
SEP 16, 2020
Generic Cholesterol-Lowering Drugs Save Money
Generic Cholesterol Drugs Are Saving Money Between 2014 to 2018, there has been a switch from brand name to generic chol ...
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
Loading Comments...